Relay Therapeutics, Inc. is a pharmaceutical company based in the United States focused on precision medicine. With a medium ESG risk rating score of 20.9, the company is dedicated to transforming drug discovery through advanced computational and experimental technologies. By using their Dynamo platform, Relay Therapeutics aims to develop life-changing therapies for patients by targeting previously inaccessible proteins. Their pipeline includes medicine candidates for precision oncology and genetic diseases such as RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).